Drugs / WVE-006
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06186492 | Nov 2023 → Feb 2025 | alpha 1-antitrypsin deficiency | Wave Life Sciences USA, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06405633 | Jul 2024 → Sep 2026 overdue | alpha 1-antitrypsin deficiency | Wave Life Sciences USA, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-05-18 | Wave Life Sciences USA, Inc. | Results Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing wavelifesciences.com ↗
WVE-006 generated wild-type M-AAT comprising 64% of total AAT and reduced harmful Z-AAT by 71% |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-05-18 | Wave Life Sciences USA, Inc. | Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing wavelifesciences.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WVE-006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06405633 ↗ |
| Modality | Oligonucleotide (other) | “RNA editing oligonucleotide” NCT06186492 ↗ |